SATELLOS BIOSCIENCE INC - MSCLF STOCK NEWS

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) announced promising results from a pilot study of SAT-3247, their oral small molecule treatment for Duchenne muscular dystrophy (DMD), in a canine model. After four months of daily treatment:

- Muscle function returned to near-normal levels compared to healthy animals
- Increased Regenerative Index (RI) in diaphragm, calf, and quadriceps muscles
- No adverse events or significant changes in hematology or clinical chemistry
- Trends towards lower creatine kinase levels, potentially indicating disease modification

The data will be presented at the 29th Annual Congress of the World Muscle Society in October 2024. Satellos believes these results are groundbreaking, especially given the severity of the canine DMD model compared to mouse models.

Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) has initiated a Phase 1 clinical study for SAT-3247, a novel oral small molecule drug targeting AAK1. The drug is designed to regenerate skeletal muscle in Duchenne muscular dystrophy (DMD) and other muscle degenerative conditions. The study comprises two components:

1. A trial with 72 healthy volunteers to assess safety and pharmacokinetics, including single-ascending dose (SAD), multiple-ascending dose (MAD), and food effect cohorts.

2. A 28-day, open-label, single dose cohort with 10 adult DMD patients, expected to begin in late Q4 2024.

Initial safety and pharmacokinetic data are anticipated in Q4 2024, with the DMD patient component starting in Q1 2025.

Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF), a biotech company developing new small molecule therapeutics for muscle diseases, has announced its participation in two upcoming investor conferences in New York City. CEO Frank Gleeson and CFO Elizabeth Williams will represent the company at these events:

1. H.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on Wednesday, September 11th at 8:00 a.m. ET

2. Cantor 2024 Global Healthcare Conference: Fireside chat on Thursday, September 19th at 9:45 a.m. ET

Both presentations will be available via live webcast on the company's website, with replays accessible afterwards.

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) has announced the acceptance of a regulatory filing to commence a Phase 1 clinical trial for SAT-3247, a potential oral treatment for Duchenne muscular dystrophy (DMD). The trial, expected to begin dosing in Q3 2024, will be conducted in Australia under the Therapeutic Goods Administration's Clinical Trial Notification scheme.

The study will consist of two parts: 72 healthy volunteers will participate in single-ascending dose, multiple-ascending dose, and food effect cohorts to assess safety and pharmacokinetics. Additionally, 10 adult DMD patients will be enrolled in a 28-day, open-label cohort to compare data and explore pharmacodynamic markers. This milestone marks Satellos' advancement into clinical development with a novel small molecule approach aimed at restoring muscle regeneration and repair in DMD patients.

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) announced its Q2 2024 financial results and operational highlights. Key points include:

• Updated canine DMD model data showing 195% improvement in muscle force over baseline at four months
• Receipt of Orphan Drug and Rare Pediatric Disease designations from US FDA for SAT-3247
• On track to initiate Phase 1 clinical trial with SAT-3247 in Q3 2024
• Cash balance of $27.7 million as of June 30, 2024
• Net loss of $6.0 million ($0.05 per share) for Q2 2024
• Increased R&D expenses to $4.9 million, up from $1.6 million in Q2 2023
• General and administrative expenses increased to $1.8 million from $1.5 million in Q2 2023

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) has received Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247, its potential treatment for Duchenne muscular dystrophy (DMD). This follows the earlier Orphan Drug Designation for the same drug. SAT-3247 is a first-in-class oral small molecule designed to restore muscle regeneration and repair, regardless of dystrophin or exon mutation status.

Key points:

• DMD is a rare genetic disorder causing progressive muscle degeneration
• Rare Pediatric Disease Designation may lead to a priority review voucher
• Orphan Drug Designation offers potential 7-year market exclusivity and other benefits
• Phase 1 clinical trial of SAT-3247 is anticipated in Q3 2024

Satellos Bioscience has submitted a clinical research proposal to Australia's Human Research Ethics Committee (HREC) on July 10, 2024, to start a Phase 1 trial for SAT-3247, an oral drug aimed at regenerating skeletal muscle in Duchenne muscular dystrophy (DMD) and other conditions. Expected to begin in Q3 2024, the trial will enroll healthy volunteers to assess safety and pharmacokinetics. Following successful preclinical and toxicology studies, this milestone marks Satellos' transition to a clinical-stage company. SAT-3247 could move to trials with DMD patients by early 2025, pending regulatory approvals.

Satellos Bioscience has announced promising preliminary results from a single case study of their SAT-3247 treatment in a canine model of Duchenne muscular dystrophy (DMD). The study reported a significant improvement in muscle repair and regeneration, with a 450% increase in the Regenerative Index after four months of treatment and up to a 100% increase in muscle force after two months. These findings were presented at the Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference. Satellos plans to initiate Phase 1 clinical trials in Q3 2024.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) announced that CEO Frank Gleeson will be participating in a panel discussion at the Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference in Orlando, Florida, from June 27-29, 2024. This event underscores the company's ongoing commitment to developing innovative treatments for Duchenne muscular dystrophy. Gleeson highlighted Satellos' progress, supported by a programmatic investment from PPMD in 2021, towards creating an oral drug candidate aimed at improving treatment options for Duchenne patients. The company plans to submit a regulatory package in July 2024 to begin a Phase 1 clinical trial of SAT-3247, evaluating its safety and pharmacokinetics in healthy volunteers in Q3 2024.